

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this 21st day of February 2002.

By _____

Carol A. Senn
(Signature of person mailing)

Rec'd

Carol A. Senn
(Typed or printed name of person)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

HARRY R. HOWARD, JR.

Examiner: Not Yet Assigned

APPLICATION NO.: 10/010,651

Group Art Unit: Not Yet Assigned

FILING DATE: December 6, 2001

TITLE: COMBINATION TREATMENT FOR
ANXIETY, DEPRESSION, OBSESSIVE
COMPULSIVE DISORDER AND PSYCHOSIS

Commissioner for Patents
Washington, D.C. 20231

Sir:

REQUEST FOR CORRECTED FILING RECEIPT

Attached is a copy of the Official Filing Receipt received from the Patent and Trademark Office in the above-identified application. Issuance of a correct filing receipt is respectfully requested due to an error in the entry of the application inventors.

The correct "publication date" should be listed. This is a chemical case and no "Sequence Disclosures" are needed. Please update your records accordingly and issue a corrected filing receipt.

Respectfully submitted,

Solene W. Appleman
Solene W. Appleman
Attorney for Applicant(s)
Reg. No. 35,428

Pfizer Inc
Patent Department, 5th Fl.
150 East 42nd Street
New York, NY 10017-5612
(212) 733-3552




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/010,651	12/06/2001	1614	938	PC11839A		30	2

23913
PFIZER INC
150 EAST 42ND STREET
5TH FLOOR - STOP 49
NEW YORK, NY 10017-5612



CONFIRMATION NO. 4848

FILING RECEIPT



OC000000007439322

Date Mailed: 02/07/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Harry R. Howard JR., Bristol, CT;

JWA
C

Assignment For Published Patent Application

Pfizer Inc.;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/272,619 03/01/2001

Foreign Applications**If Required, Foreign Filing License Granted 01/25/2002****Projected Publication Date:** To Be Determined - pending completion of Sequence Disclosures**Non-Publication Request:** No**Early Publication Request:** No**Title**

Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis

Preliminary Class

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this 21st day of February 2002.

Carol A. Senn
(Signature of person mailing)

Carol A. Senn
(Typed or printed name of person)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

HARRY R. HOWARD, JR.

APPLICATION NO.: 10/010,651

Examiner: Not Yet Assigned

FILING DATE: December 6, 2001

Group Art Unit: Not Yet Assigned

TITLE: COMBINATION TREATMENT FOR
ANXIETY, DEPRESSION, OBSESSIVE
COMPULSIVE DISORDER AND PSYCHOSIS

Commissioner for Patents
Washington, D.C. 20231

Sir:

REQUEST NOT TO COMPLY WITH SEQUENCE DISCLOSURE


Attached is a copy of the Notice To Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

The captioned case is a chemical case and does not have a Nucleotide Sequence or Amino Acid Sequence to comply with. Therefore there is no sequence to send to the Patent Office.

Respectfully submitted,

Jolene W. Appleman
Jolene W. Appleman
Attorney for Applicant(s)
Reg. No. 35,428

Pfizer Inc
Patent Department, 5th Fl.
150 East 42nd Street
New York, NY 10017-5612
(212) 733-3552



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/010,651	12/06/2001	Harry R. Howard JR.	PC11839A

CONFIRMATION NO. 4848

23913
PFIZER INC
150 EAST 42ND STREET
5TH FLOOR - STOP 49
NEW YORK, NY 10017-5612

FORMALITIES LETTER



OC00000007439323

Date Mailed: 02/07/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Ahmed

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

THIS PAGE BLANK (USPTO)